Cat · Felis catus · typical adult weight 2.50–7.00 kg
Tofacitinib is dosed at 0.5–1 mg/kg PO q12h in cats, per Papich Handbook of Veterinary Drugs, 5th Ed. Tofacitinib is used in cats for Immune-mediated disease (investigational). Routes documented in cats: PO. A typical adult cat weighs 2.50–7.00 kg. ExoticRx lists 1 cited dose rule for Tofacitinib in cats, drawn from published veterinary references. Verify against current literature before clinical use.
US trade names: Xeljanz
| Route | Dose | Frequency | Duration | Indication | Evidence | Source |
|---|---|---|---|---|---|---|
| PO | 0.5–1 mg/kg | q12h | Per protocol | Immune-mediated disease (investigational) | Extrapolated | Papich Handbook of Veterinary Drugs, 5th Ed |
Need the exact dose for your patient?
These ranges are per kg. Enter your cat's weight to get the precise dose and draw-up volume — unit and concentration math done for you.
Janus kinase (JAK1/JAK3) inhibitor that blocks signaling of multiple cytokines involved in inflammation and immune response (IL-2, IL-4, IL-6, IL-15, IL-21, IFN).
Investigational in veterinary medicine. Immunosuppression, infection risk. Monitor CBC. May cause GI upset. Potentially useful for immune-mediated diseases unresponsive to standard therapy.
Species-specific contraindications and adverse-reaction reports for cats may differ from canine / feline reference data — consult the primary citations listed with each rule.
Tofacitinib dose range in cats, with cited source references: PO 0.5–1 mg/kg q12h. Reference ranges from cited sources — verify against current literature before clinical use.
Documented routes for Tofacitinib in cats: PO.
Cited course lengths for Tofacitinib in cats include: Per protocol. Duration depends on the indication — match it to the specific dose rule in the table above.
Tofacitinib is indicated in cats for: Immune-mediated disease (investigational).
These are general warnings for Tofacitinib across species; consult the cat dosing table above for species-specific guidance. Investigational in veterinary medicine. Immunosuppression, infection risk. Monitor CBC. May cause GI upset. Potentially useful for immune-mediated diseases unresponsive to standard therapy.
Why a species-specific page? Tofacitinib pharmacokinetics differ across species: dose ranges, intervals, and route preferences are not interchangeable. Cross-extrapolation from canine doses is unsafe in cats — the rules above are the citations specific to this species, not generic recommendations.
Sourced from published veterinary references; awaiting credentialed clinical reviewer. See our editorial process. Reference only — not veterinary advice.